Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® technologies, AmoyDx has a market-leading portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include but not limit to single gene testing kits, multi-gene testing panels, NGS panels and NGS analytical systems. In the past years, more than 20 diagnostic kits have been approved by the Chinese authorities, the NMPA and in Europe (CE mark). In several External Quality Assessment (EQA) programs, including EMQN and PQCC, AmoyDx is the NO. 1 testing kit supplier for years and always achieves the highest accuracy rates. Nowadays, AmoyDx serves an extensive domestic and international oncology network, reaching over 500 top hospitals in China and over 50 countries worldwide. Every year hundreds of thousands of cancer patients benefit from AmoyDx products and services. As diagnostic partner with AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Eisai, Hengrui and BeiGene, AmoyDx provides diagnostic products and services for trials of drugs in clinical development and for clinical practice. AmoyDx® ROS1 kit was the first approved companion diagnostic kit for Pfizer's crizotinib by Japanese and South Korean authorities. Our mission is to improve healthcare and patients' lives with superior & innovative products and services. Our vision is to be one of the global leading and most reliable suppliers of quality diagnostic products and services for personalized healthcare.